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Sunmnary The development of resistance to melphalan, cis-platinum and cyclophosphamide has been
examined in the MT murine mammary carcinoma. A gradual decrease in therapeutic response was detected
using growth delay and clonogenic cell survival during repeated drug treatment. A slow rate of resistance
development, a gradual change in the slope of the dose-survival curves and the inability of 180mgkg-
cyclophosphamide to bring about a reduction in tumour response at a faster rate than 60mgkg-1
cyclophosphamide suggest that resistance development was not due to the selection of a pre-existing highly
drug resistant sub-population of tumour cells. Partial drug-resistance is proposed as one possible reason for
the apparent inconsistency between these data and existing models of drug-resistance development. The drug-
resistant lines were characterized for karyotype, DNA content and cell volume, but only the cyclo-
phosphamide-resistant line showed any significant difference from the wild-type tumour. Cross-resistance
studies revealed some inconsistencies with previous reports. Also, resistance to cyclophosphamide developed
more quickly in the line which was resistant to melphalan, than in the wild-type tumour, despite the initial
appearance of little cross-resistance. This increased rate of resistance development may be important in
salvage chemotherapy.
Drug resistance is commonly encountered in cancer
chemotherapy. Some tumours never respond to
cytotoxic drug treatment, while others initially
respond well, but eventually regrow and are then
resistant to the originally effective drug. This
acquired resistance may be due to changes
occurring in the host which alter the pharma-
cokinetics of the drug (Priesler, 1982). However, the
most commonly quoted reason for the development
of drug resistance in tumours is the emergence of
tumour cells with a lower drug sensitivity.
Two types of study have demonstrated that
tumour cell populations may be heterogeneous with
respect to chemosensitivity. Firstly, diversity has
been shown to exist in the sensitivity of sub-lines
isolated from tumours (Heppner et al., 1978;
Stephens & Peacock, 1982; Brouwer et al., 1983)
and secondly, highly drug-resistant cells have been
isolated from treated tumour cell populations that
are mainly composed of sensitive cells (Clements,
1975). It is studies of this second type which have
led to the suggestion that pre-existing highly drug-
resistant cells within a tumour may be responsible
for the inability to cure some tumours by chemo-
therapy (Goldie & Coldman, 1979) and may
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explain the development of drug-resistant tumours
during chemotherapy (Skipper et al., 1978).
Skipper et al. (1978) produced data mainly using
murine leukaemias which supported the idea that
acquired drug-resistance may be due to the
selection of a pre-existing highly drug-resistant sub-
population of tumour cells. However, this is one of
the few studies in which the rate of development of
drug-resistance in vivo has been investigated. It was
therefore the aim of the work described here to
examine the validity of this model in a trans-
plantable murine mammary tumour, the MT
carcinoma. Studies were performed with melphalan,
cyclophosphamide and cis-platinum. These drugs
are used commonly to treat human cancer and they
have been shown to be susceptible to the
acquisition of drug-resistance in both human
(Bergsagel et al., 1972) and experimental (D'Incalci
et al., 1983; Schmid et al., 1980; Seeber et al., 1982)
tumours.
Materials and methods
Tumours and mice
MT carcinoma (caMT) was maintained in male
WHT mice by i.m. transplant of tumour brei
bilaterally into the gastrocnemius muscles. WHT
mice were obtained from the Institute of Cancer
Research breeding centre and were used when they
were 8-10 weeks old and weighed 28-34g. Tumours
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were used for experiments when they were 0.15-
0.25g.
Cytotoxic drug treatment
Melphalan ('Alkeran', The Wellcome Foundation
Ltd.), cyclophosphamide (CY, Farmatalia Carlo
Erba Ltd.) and cis-platinum (cis-Pt, cis-diammine-
dichloroplatinum II, donated to the Department of
Biochemical Pharmacology, ICR by the Johnson
Matthey Research Centre) were administered by the
intra-peritoneal route to non-anaesthetised mice for
growth delay and clonogenic cell survival studies.
For in vitro cytotoxic drug treatments 5ml
aliquots of a single-cell suspension at a concentra-
tion of 1 to 4x105 cellsml-l were incubated at
37°C for 1.5 to 2.5h. The cells were then incubated
with drug for 1 h, with continuous gentle agitation,
the drug-containing medium removed and the cells
resuspended in culture medium. The colony
forming ability was assayed as described below.
Preparation ofcell suspensions
Tumour cell suspensions for in vitro drug treatment
and in vitro cell survival assessment were prepared
using the method of Stephens et al., 1980. Tumour
tissue was excised aseptically and chopped finely
with crossed scalpels. Following one wash in PBSA
the tissue was incubated at 37°C with continuous
gentle agitation for 30min in PBSA containing
0.2% trypsin (Bacto-trypsin, Difco Laboratories)
and 0.05mgml - I Deoxyribonuclease (DNase-I,
Sigma Chemical Co.) The suspension was then
given ten vigorous shakes to dislodge loosely
attached cells and to disperse loosely adhering
clumps of cells. Remaining clumps were removed
by filtering the digest through 35gm polyester
mesh. The cell suspension was washed and re-
suspended in Hams F12 culture medium containing
antibiotics and 17% donor calf serum. The cell
suspension was counted using a haemocytometer,
care being taken to distinguish between host cells
and tumour cells (Stephens et al., 1978). The cell
yield from untreated tumours was usually in the
range I to 8 x 107 cellg'-.
In vitro clonogenic cell survival assay
The survival of tumour cells after either in vivo or
in vitro drug treatment was assessed using the
double-layer soft agar clonogenic assay developed
by Courtenay (1976). The only modification was
that red blood cells were not added to the culture
medium, since they did not increase the cloning
efficiency of caMT. The effect of in vitro drug
treatment was expressed as surviving fraction but
after in vivo treatment the fraction of surviving cells
per tumour was used. This was calculated as the
ratio of the number of colony-forming tumour cells
in treated and untreated tumours. Points from all
individual experiments have been included on the
survival curves to give an indication of the
variability and reproducibility of the data.
Measurement of tumour growth delay
A calibration curve technique was used to
determine the size of tumours in situ. The tumour-
bearing leg was passed through holes of known
diameter in a perspex disc and the size of the
tumour was taken to be the size of the largest hole
through which the tumour would pass without
resistance (Stephens et al., 1984). This size was
converted into tumour weight by comparison with
a calibration curve which was constructed by
measuring a number of tumours, dissecting them
out and weighing them.
A minimum of six tumours per group were used
in growth delay experiments. Tumours were
measured every day and the time taken for each
individual tumour to increase in weight by a factor
of 4 was determined (T4x). Growth delay (GD)
was then calculated as the difference in the median
T4 x of the treated and untreated groups.
Karyotype analysis and DNA content
Preparation of cells for karyotype was by standard
techniques. Tumour cell suspensions were allowed
to grow in monolayer for 18h, exposed to colcemid
(0.4upgml-1, Gibco Diagnostics) for 2h, harvested
and incubated for 5min in 0.075M potassium
chloride. Cells were fixed in methanol/glacial acetic
acid (3:1) and dropped onto clean glass microscope
slides. Slides were stained in 4% Giemsa stain
(BDH Chemicals Ltd.) for chromosome counting.
For DNA analysis cells were stained with ethidium
bromide using the method of Vindel0v (1977) and
DNA content was measured with an Ortho
Cytofluorograf 50H system (Ortho Instruments,
Mass, USA).
Results
Development ofdrug-resistance
In order to develop drug resistance, caMT was
treated in consecutive passages with single doses of
melphalan, CY or cis-Pt. At each tumour passage,
the first treated tumour to reach a size of four
times its weight at the time of treatment was used
to implant tumours for the next passage. Each
agent was administered at the maximum dose which
did not kill any mice (12mgkg-1 melphalan,
O0mgkg 1 cis-Pt and 180mgkg-CY). CY was
also used at 60mgkg- I for some experiments.RATE OF DRUG-RESISTANCE DEVELOPMENT 825
Figure 1 shows changes in growth delay
produced by repeated drug treatments with each
drug. In each case there was a gradual development
of drug resistance. The GD produced by
12mgkg 1 melphalan dropped from 8.6d to 2.1 d,
a reduction factor of 4.1 (GD in previously
untreated tumour/GD in treated tumour), after 16
treatments. Twenty treatments with 180mgkg- 1 CY
reduced the growth delay produced by this dose
from 15.9 to 1.5 days, a factor of 10.6, and 19
treatments with 10mgkg-1 cis-Pt reduced the
growth delay from 9.2d to 2.4d, a factor of 3.8.
To test the effect of dose on the rate of
development of resistance an experiment was
performed with CY at two dose levels. Treatments
were again given at each passage. In one case each
dose was 60mgkg-1 CY and in the other
180mgkg-1 CY was used. For each the GD
produced by both 60mgkg-1 and 180mgkg-1 CY
was measured at every passage (Figure 2).
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Figure 1 Development of drug-resistance. Growth
delay produced by given doses during repeated
treatment with (a) 12mgkg-1 melphalan; (b)
10mgkg-1 cis-platinum; (c) 180mgkg-1 (O,OEl) and
60mgkg-1(0) cyclophosphamide.
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Figure 2 The effect of drug dose on the rate of
resistance development. The growth delay produced by
(a) 60mgkg-1 and (b) 180mgkg-1 cyclophosphamide
during repeated treatment with either 60mgkg-1
(--*--) or 180mgkg-1 (-El ) cyclophosphamide
at each passage.
The results show that treatment with a higher
dose of drug does not bring about drug resistance
more quickly than a lower dose. This was
unexpected since, if resistance development was due
to the selection of a pre-existing highly drug-
resistant sub-population of tumour cells, the higher
dose should eliminate sensitive cells more quickly
and bring about a more rapid loss of tumour
response.
Clonogenic cell survival after in vivo treatment
The results of cell-survival studies on the lines
which had received multiple drug treatments are
given in Figure 3. The dose-survival curve for the
line which had received 16 melphalan treatments
(MTME16) measured 18h after treatment is
exponential through the origin and has a D10 (dose
to reduce survival by one log) of 7.8mgkg-1,
which compares with 2.6mgkg-1 for wild-type
caMT. This indicates a resistance factor (D1o of
resistant tumour/D1o of sensitive tumour) of 3.
This difference in slope was statistically significant
(P<0.01) when the curves fitted by linear
regression were compared using a t test.826 T.J. McMILLAN et al.
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Figure 3 Dose-survival curves after in vivo treatment for lines which had received (a) 8 (MTME8, l) or 16
(MTME16, 0) treatments with 12mgkg-1 melphalan; (b) 20 treatments with 10mgkg-1 cis-platinum
(MTCP20, 0) or (c) 16 treatments with 180mgkg-1 cyclophosphamide (MTCY16, 0). Curves for wild-type
caMT are given for each drug (C).
For the tumour which had received 8 previous
treatments with melphalan the melphalan dose-
survival curve had a D1o of 5.6mgkg-1. A
negative intercept (n=0.78) was suggested when the
data were fitted by least squares regression analysis
but the errors on the fitted curve were such that the
extrapolation number was not significantly different
from one. Since the D1o value of this curve is less
than that seen after 16 previous treatments, a
simple selective process on a pre-existing drug-
resistant sub-population may not fully explain the
development of resistance in this case.
Clonogenic cell survival assays performed on
tumours which had received 20 treatments with cis-
Pt (MTCP20) indicated that a change in the slope
of the dose survival curve had accompanied the fall
in growth delay. The D10 increased from 2.9mgkg
to 5.25mgkg-1 (Figure 3b).
The in vivo dose-survival curve for MTCY16,
which had received 16 treatments with CY is given
in Figure 3c. A D10 of 57mgkg- 1 and an
extrapolation number of 1.2 compares with
14.9mgkg-1 and 3.3 for the untreated caMT.
There was therefore a significant decrease in the
slope of the curve (P<0.001, t test).
Clonogenic cell survival assays were also
performed at each passage during repeated
treatment with 60mgkg-1 CY. Table I shows the
parameters of the survival curves. The tumour
showed little response to 60mgkg-1 CY after 5
treatment passages according to a growth delay
endpoint (Figures Ic, 2a) and this acquired
resistance was associated with changes in the shape
of the survival curve (D1o increased from 14.9 to
Table I Parameters of cyclophosphamide dose-survival
curves during repeated in vivo treatment with 60mgkg-1
cyclophosphamide. (Figures in brackets are 95%
confidence limits)
Survival curve parameters
Number ofprevious
treatments D1o(mgkg-1) n
0 14.9 2.6
(13.2-17.1) (1.2-5.4)
1 21.7 5.6
(17.2-29.3) (1.7-18)
2 15.1 15.0
(11.2-23.4) (1.9-122)
3 27.7 3.0
(19.0-50.9) (0.9-10.4)
4 35.1 1.6
(26.3-52.8) (0.7-3.8)
5 35.4 1.3
(26.7-52.7) (1.6-2.9)
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35.4mg/kg-1). The extrapolation numbers were
poorly defined by the data and the trends in this
parameter were not significant.
Clonogenic survival after in vitro treatment
The results of clonogenic cell survival assays
following in vivo treatment can be influenced by
factors other than inherent cellular sensitivity.
However, some of these problems can be overcome
by treating cells in vitro for 1 h and when this was
done significant differences were again seen between
the wild-type caMT and the drug resistant lines.
Figure 4a shows that MTME16 had a D1o of
1.9ugmlP- compared with 0.63ugml-1 for caMT
(P<0.001, t test) and the resistant line also has a
small shoulder on the curve (extrapolation
number= 1.5).
The in vitro cis-Pt dose-survival curve for
MTCP20 is shown in Figure 4b. There appears to
be a change in slope (DIo value of 4.7ugmlP-
compared with 3.1 ugml-1 for wild-type caMT)
and a slight increase in the size of the shoulder
(extrapolation number= 1.5 compared to 1 for
wild-type caMT).
Karyotype, DNA content and cell volume
The distribution of chromosome numbers for the
wild-type MT carcinoma was stable during one
year of continuous passage in vivo. The modal
chromosome number was 73 (range 50-80) and one
metacentric marker chromosome was present in
95% of the cells. A slight drop in the modal
chromosome number was detected for MTME16
and MTCP15 (modes of 69 and 68 respectively,
Table II) and all of the metaphases analysed had a
metacentric marker chromosome.
MTCY16 had fewer chromosomes than the wild-
type MT carcinoma, with a mode at 63/64
chromosomes and a range of 36-154. A sub-
metacentric marker chromosome was present in
70% of the cells. This differed from wild-type
caMT in which the marker was metacentric. When
the cells of MTCY16 were analysed immediately
after the cessation of treatment all cells had at least
two double minutes, which have been shown to be
associated with gene amplification in some cases.
These double minutes were not present when
MTCY16 had been passaged 24 times without
treatment although the line retained resistance to
CY.
Table II also shows that MT and MTME16 had
identical DNA contents (Relative G, DNA content,
RGD = 1.9) and although MTCP15 was lower than
wild type caMT (RGD= 1.8) it was within the
range of values for different samples of wild-type
tumour (1.8-2.0). The DNA content for MTCY16,
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Figure 4 Dose-survival curves after in vitro treatment
for lines which had received (a) 16 treatments with
12mgkg-' melphalan (MTME16,-0) or (b) 20 treat-
ments with 10mgkg-' cis-platinum (MTCP20, 0).
Curves for wild-type caMT are given for each
drug (O).
however, appeared to be significantly lower than
wild-type caMT (RGD= 1.6).
The peak cell volume for wild-type caMT and the
three drug resistant lines were measured with a
Coulter counter and pulse height analyser.828 T.J. McMILLAN et al.
Table II Properties of drug-resistant lines of caMT
Wild-type ME16 CY16 CP15
DNA content (RGD)' 1.9 1.9 1.6 1.8
Modal chromosome number 73 69 63 68
Peak cell volume (jim3) 1075 1061 918 1026
Tumour volume doubling 0.8 0.9 0.9 0.9
timeb (days)
aRGD=Relative G1 DNA content (ratio of G1 peaks of tumour cells and host
cells); bCalculated from time to grow from 0.1 to 0.5g.
MTCY16 was the only line which differed
significantly (P<0.01, Mann-Whitney U test) from
wild type MT carcinoma, and this had a 15%
reduction in the mean peak cell volume (Table II).
This was consistent with the reduction in DNA
content and chromosome number seen in
MTCY16.
Tumour growth rate
Although the volume doubling time values for the
resistant lines were greater than for wild-type caMT
(Table II) these differences were not significant
(Mann-Whitney U test).
The stability ofdrug resistance
The growth delay produced by 12mgkg1
melphalan in MTME16 did not change significantly
in 29 untreated passages. However, both MTCP15
and MTCY16 increased in sensitivity in the first
few passages after treatment vk as stopped. The
growth delay produced by 10mg kg I cis-platinum
increased from 0.2d to 4.9d in the first 6 passages
of MTCP15 but it was still 4.1 d after 12 untreated
passages compared with 9.2d for the wild-type
tumour. Similarly for MTCY16 the growth delay
produced by 180mgkg- 1 cyclophosphamide
increased from 1.5 to 6.8 d after 7 untreated
passages but was 6.7d after 24 passages, still a
significant reduction from the 15.9d growth delay
seen in the wild-type caMT.
Cross-resistance studies
Cross-resistance patterns in the drug-resistant lines
were studied by in vitro treatment followed by
clonogenic cell survival estimation (Table III).
Cross-resistance between cis-Pt and melphalan was
evident in both the cis-Pt-resistant (MTCP15) and
melphalan-resistant (MTME16) lines. Likewise,
there was an increase in the D1o value of the cis-
platinum dose-survival curve in the CY-resistant
line (MTCY16). Thus these results confirm the
general finding that cis-Pt is cross-resistant with
alkylating agents.
MTCY16 showed a decreased sensitivity to
melphalan, as would be expected from the similar
modes of action of these two drugs. In MTME16
the growth delay produced by 180 mgkg- 1 CY
(13 d) was slightly lower than that in wild-type
caMT (15d). Although this difference was small it
was noted that when the melphalan-resistant line
was repeatedly treated with 180 mgkg- 1 CY,
resistance to CY developed more quickly than in
Table III Cross-resistance studies. Slopes of dose-survival curves following in vitro treatment (D1o for
drugs in jMgml-1 and Do in Gy for y-radiation). Values in brackets give ratio of slopes of curves for
resistant line and wild-type caMT
Tumour line Melphalan cis-platinum VP16 Bleomycin Vindesine CBDCA y-ray
Wild-type 0.63 3.1 8.6 22 2.5 109 1.5
ME16 1.9 5.7 1.4
(3.0) (1.8) (0.93)
CPI5 1.1 4.7 8.1 22 3.8 286 1.5
(1.7) (1.5) (0.94) (1.0) (1.52) (2.6) (1.0)
CY16 1.04 5.8 1.3
(1.65) (1.9) (0.87)RATE OF DRUG-RESISTANCE DEVELOPMENT 829
wild-type caMT (Figure 5). After 4 treatments,
for example, the growth delays for the two experi-
ments with MTME16 were 4.3 and 7.9d while in
three series with caMT it was 14.6, 9.9 and 13.3d.
Resistance to melphalan was still evident after 8
treatments with CY.
VP16 and bleomycin have been used in
combination with cis-Pt in the treatment of some
tumours (Kelson et al., 1978; Sierocki et al., 1979)
and the lack of cross-resistance between cis-Pt and
these drugs in MTCP15 (Table III) supports this
use. However, vindesine, which was shown by
Seeber et al. (1982) to demonstrate collateral
sensitivity in a cis-Pt resistant tumour line,
demonstrated cross-resistance with cis-Pt in
MTCP15.
CBDCA (cis-diammine-1, 1-cyclobutane dicarbo-
xylato platinum II), an analogue of cis-platinum
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Figure 5 Development of resistance to 180 mgkg-1
cyclophosphamide in the melphalan-resistant line of
caMT (MTME16, O and [l are two independent
experiments). The dashed line indicates the
development of cyclophosphamide-resistance in wild-
type caMT from Figure lc.
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Figure 6 Actual development of resistance to
melphalan in caMT (0) compared with a two-
compartment model involving sensitive cells plus a
completely resistant sub-population of cells (---) or a
partially resistant sub-population ( ). Calculations
were based on D1o values of 2.6mgkg-1, 7.8mgkg-'
and infinity for the sensitive, partially resistant and
completely resistant tumour cells.
which has been reported to be less toxic than cis-Pt
(Harrap et al., 1980), was also less effective in the
cis-Pt resistant line than in wild-type caMT.
None of the drug-resistant lines showed any
significant change in the response to y-radiation.
Discussion
The acquisition of drug-resistance in tumours is an
important clinical problem which is still far from
being fully understood. In this paper we have
examined the development of resistance to three
commonly used antitumour agents, melphalan, cis-
platinum and cyclophosphamide in a murine
mammary carcinoma and have found that existing
models of drug-resistance development do not
adequately explain the results obtained.
Repeated high dose drug treatment was found to
bring about a reduction in tumour response as
assayed by growth delay and clonogenic cell
survival after in vivo and in vitro drug treatment.
The degree of resistance achieved varied according
to how this parameter was defined. For example,
the growth delay induced by 12mgkg-1 melphalan
was reduced by a factor of 4.1, while the ratio of
the slopes of the dose-survival curves after
clonogenic cell assay was 3.0 after both in vivo and
in vitro treatment. This may reflect non-linearity in
the dose-response curves and emphasizes the
importance of using more than one assay to define
therapeutic response.
Gross karyotypic differences between drug-
sensitive and resistant tumour lines are a common
finding (Parsons & Morrison, 1978; Peacock et al.,
1982; Tew et al., 1983). In caMT there was a
tendency for a lower modal chromosome number in
the drug resistant lines. In the case of the
cyclophosphamide-resistant line (MTCY16) this
difference was large and was accompanied by a
significant reduction in DNA content and cell size.
Whether this is directly related to the drug-resistant
phenotype is not known. The presence of double
minute chromosomes in MTCY16 suggests that
some genes may have been amplified since double
minutes in cell populations resistant to metho-
trexate have been shown to reflect gene
amplification (Schimke et al., 1978). There is no
documented evidence of gene amplification in
alkylating agent-resistant cells, although Tew et al.
(1983) did find double minutes in an alkylating
agent-resistant subline of the Walker 256 breast
carcinoma cell line. Double-minutes are often lost
at mitosis when the selection pressure of drug
treatment is removed (Kaufman et al., 1979). This
seems to have occurred here because after 24
untreated passages of MTCY16 the double minutes
, I E
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were no longer present. However, since at this time
the line was still much more resistant than the wild-
type tumour it would seem that double minutes
were not uniquely associated with cyclo-
phosphamide resistance. Alterations in the chromo-
some number distribution and in the marker
chromosome were stable after cessation of drug
treatment but it is not known how these might
relate to cyclophosphamide resistance.
Analysis of the rate of tumour volume increase
indicated that resistance to the three drugs used in
this study was not due to changes in the growth
rate during drug treatment. This confirms the
findings of studies on other alkylating agent-
resistant lines (Parsons & Morrison, 1978; Ball et
al., 1966).
It was observed that melphalan resistance in
MTME16 was stable when assayed using growth
delay during passage without drug treatment.
However, in MTCY16 and MTCP15 stability of
resistance was only found after partial return of
sensitivity, suggesting that perhaps two
mechanisms, one stable and the other unstable,
were involved in resistance in these two lines. Stable
genomic changes are therefore likely to have been
responsible for at least part of the resistance
observed following treatment with the three drugs
studied here. This is consistent with some reports of
the stability of resistance to alkylating agents
(D'Incalci et al., 1983; Frondoza et al., 1982;
Schabel et al., 1978) although it is not a universal
phenomenon since in other systems the resistance
phenotype was found to be highly unstable
(Berman & Steel, 1984).
Patterns of cross-resistance often show inconsis-
tencies between different tumour systems, which
makes their interpretation very difficult. This is
demonstrated here by the observation of cross-
resistance between cis-Pt and vindesine, when the
only previous study on these two drugs showed
collateral sensitivity (Seeber et al., 1982). The
increased rate of CY-resistance development in
MTME16 may be a reflection of such variations
within a single tumour. Figure 5 suggests that the
majority of the cells in MTME16 were not resistant
to CY but a CY-resistant cell population could be
rapidly selected by repeated CY treatment. This
emergence of resistance to a second drug may be
termed 'tertiary resistance' and it could be a serious
limiting factor to the success of salvage chemo-
therapy in which a new drug is used following
relapse during the course of the treatment of first
choice. Even if no cross-resistance is observed
initially when the treatment is altered, tumour
responsiveness could rapidly decline during
repeated treatment.
Current theories of drug resistance development
are based on a two-compartment model in which
the drug sensitive cells which compose the majority
of the tumour are eliminated by drug treatment,
leaving a pre-existing highly drug-resistant cell
population to predominate. Skipper et al. (1978)
produced an equation which enables the calculation
of the number of treatments required to bring
about complete drug resistance (which they define
as being when the resistant and sensitive subpopu-
lations are equal in size) if one knows the sensitivity
of the sensitive and resistant cells and the growth
kinetics of the two sub-populations. The individual
treatments used in the development of resistance to
melphalan, CY and cis-Pt in the MT carcinoma
produced at least three decades of cell kill and the
final resistant populations did not differ from the
parent caMT in their growth rate. Therefore, since
one might expect drug resistant cells to be present
at a proportion of 1 in 105 to 1 in 108 (Skipper et
al., 1978) we would have expected total resistance
within 2-3 treatments if a completely resistant sub-
population of cells was being selected. The slow
rate of resistance development seen in this system is
inconsistent with this simple model (see broken line
in Figure 6).
One factor which could influence these results is
the degree of resistance of the 'resistant'
population. In all of the reports of drug resistance
that we are aware of, resistance was not complete
even after many treatments. This was recognised by
Skipper et al. (1978) who included a 'sensitivity
factor' for resistant cells in their equation to
calculate the rate of resistance development.
However, to simplify calculations total resistance
was generally assumed.
By including a factor to take into account partial
drug resistance, the loss of therapeutic response
would be expected to occur more slowly. For
example, the development of resistance to
melphalan in caMT produced a line which had a 3-
fold decrease in the slope of the dose-survival
curve. If it is assumed that the sensitivity at the end
of the series of treatments was equal to the
sensitivity of the original resistant population, then
the reduction in the growth delay might be expected
to decrease as indicated by the full line in Figure 6.
The appearance of resistance is delayed and the
curve falls to a plateau whose height is determined
by the sensitivity of the resistant sub-population.
The resulting theoretical curve approximates more
closely to the actual data than when complete drug-
resistance is assumed, but is still not an ideal fit.
Since at the beginning of treatment the number
of resistant cells is likely to be low, the recognition
that the resistant cells have a finite sensitivity to
treatment raises the possibility of total extinction of
the resistant population. If drug resistant cells occur
at a level of 1 in 106-108, in a small tumour of
107-108 cells, a cell kill of 1-2 logs of resistant cellsRATE OF DRUG-RESISTANCE DEVELOPMENT 831
may be sufficient to kill all resistant cells. The
extinction of resistant cells may be an important
factor limiting the emergence ofMeCCNU resistance
in the LL carcinoma (Stephens, unpublished results)
as well as the drug resistance described here.
This idea could lead to the situation in which low
doses of drug bring about drug-resistance more
quickly than high doses. If a high dose ofdrug kills
a large number of sensitive cells but also kills some
'resistant' cells, resistance may develop more slowly
than at a lower dose which, although killing fewer
sensitive cells, leaves more resistant cells in the
tumour. This may be one reason why 180mgkg-1
CY did not bring about drug resistance more
quickly than 60mgkg-1 CY in caMT.
Even a consideration of partial drug resistance,
however, cannot fully explain the data presented
for caMT. With any two-compartment model of
drug resistance the expected change in the
clonogenic survival curves would be the gradual
elevation of a resistant 'tail'. Curves with slopes
between the initial wild-type caMT and the final
resistant lines were observed in caMT which would
suggest that during the course of resistance
development the tumours were composed largely of
cells with intermediate sensitivities. Therefore, to
think of a tumour simply in terms of two
subpopulations, one sensitive and one resistant,
may be misleading.
One further factor which may have some bearing
on the rate of resistance development during
treatment with high or low doses is the
mutagenicity of many anti-cancer drugs, including
the three used here. It is widely accepted that low
doses of a cytotoxic mutagen could induce more
mutants than higher doses because the relationship
between the number of surviving mutants and dose
of mutagen is often a bell-shaped curve. At higher
doses the number of mutants observed falls off
largely because of the increased cell kill. This has
been seen for both physical and chemical mutagens
in a variety of test systems (Major & Mole, 1978;
Venitt et al., 1984).
Thus, repeated treatments with low drug doses
may result in a larger drug-resistant population
than high doses of drug. This induction of drug
resistant mutants is a further factor which is not
considered in existing models describing the
development of drug resistance but it is one which
may be very important in multiple drug treatment
regimes or when multiple treatments with a single
drug are given.
Therefore, the data presented suggest that a
model involving the selection of a pre-existing
highly drug-resistant subpopulation is not adequate.
An improvement is made when partial drug-
resistance is taken into consideration but this is still
not sufficient to fully explain the data. It would
seem therefore that an alternative model for drug-
resistance development is required possibly based
on the broad spectrum of drug-sensitivities which
we and others have observed in sub-lines derived
from single tumours.
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